To contribute to the study of the genetic variability of hepatitis C virus (HCV) we have determined the nucleotide sequence of the E2/NS1 and NS3/NS4 regions of a French isolate using the polymerase chain reaction. Comparison of these nucleotide sequences with those available for American and Japanese isolates showed a significant genetic variability: 5 to 33% and 2 to 30% at the nucleic acid and amino acid levels, respectively. The genetic variability is higher in the E2/NSI (13 to 33% and 12 to 30% at the nucleic acid and amino acid levels, respectively) than in the NS3/NS4 (5 to 21% and 2 to 7%) regions. The sequence of the French isolate is more closely related to that of the American HCV prototype than to the Japanese HCV isolates. This study confirms the extent of HCV genetic variability.
Hepatitis C virus (HCV), a l0 kb positive-stranded RNA virus, has recently been shown to be the major causative agent of post transfusion non-A, non-B hepatitis Choo et aL, 1989; Hopfet aL, 1990; Kuo et aL, 1989; Miyamura et aL, 1990) . From nucleotide sequence analysis, HCV has been shown to be distantly related to the flavivirus and pestivirus families (Miller & Purcell, 1990) . As observed for these viruses, HCV has a single major open reading frame (ORF) and may encode a unique polyprotein. A portion of this polyprotein shares 20.6% amino acid sequence identity with the non-structural NS3 protein of the dengue type 2 virus of the flavivirus family (Miller & Purcell, 1990) . However, higher degrees of limited identity were found with members of the pestivirus family (bovine viral diarrhoea virus and hog cholera virus) as well as with a potyvirus (tobacco vein mottling virus) in a 190 amino acid domain of the NS3 protein (Miller & Purcell, 1990) . In addition, a statistically significant alignment (20% identity) was found in the NS5 region with carnation mottle virus spanning the putative RNA-directed RNA polymerase (Miller & Purcell, 1990) . The genetic organization of HCV has not been established experimentally. Nevertheless, from the available homology data and from recent cloning and sequencing data of the extreme 5' end which suggest a capsid-like 15 to 17 kb protein (Kato et aL, 1990; Miyamura et al., 1990; Takeuchi et al., 1990b) , it can be postulated that HCV The sequence data reported have been assigned the EMBL and GenBank nucleotide sequence databank accession number D01103.
0001-0226 © 1991 SGM shares a similar genetic organization with ftavi-and pestiviruses. Thus, the structural proteins should be encoded by the 5' part of the genome and the nonstructural proteins by the 3' part of the viral genome.
Recently, nucleotide sequences of HCV genomes isolated from American, Italian and Japanese carriers were published (Enomoto et aL, 1990; Kato et al., 1989; Kubo et aL, 1989; Okamoto et al., 1990; Takeuchi et al., 1990a, b; Weiner et al., 1991; Choo et aL, 1991) . A significant genetic variability was apparent between the different HCV strains. From the sequence data, Okamoto et al., (1990) and Enomoto et al. (1990) have proposed classifying the HCV strains into two groups. In order to define the genetic variability of a French HCV strain, we have determined the nucleotide sequence corresponding to the E2/NS1 and part of the NS3 and NS4 viral genes.
To obtain the nucleotide sequence of the NS3/NS4 region for a French HCV isolate (HCVE1), cDNA was synthesized from RNA extracted directly from human serum using a specific oligonucleotide as primer (NS4, Table 1 ) and murine reverse transcriptase (European patent application no. 88310922.5). The cDNA was subsequently amplified by polymerase chain reaction (PCR) after addition of a second specific oligonucleotide primer (NS3, Table 1), which was located 943 nucleotides upstream from the first one. The specificity of the amplification was confirmed by hybridization with a specific oligonucleotide probe (NS3/NS4) ( Table 1 ). The amplified DNA was cloned into M13mpl9 and the nucleotide sequence of five independent clones was (Fig. 1 b) . These point mutations led, for the most part, to conservative amino acid substitutions. When the sequences of five independent HCVE1 clones were compared, a divergence of 19 nucleotides was observed ( Fig. la) . At least 10 of the nucleotide changes were found on two distinct clones. Twelve of the mutations induced amino acid changes and one led to the appearance of a stop codon at positions 258 to 260.
To obtain the complete E2/NS1 gene sequence for HCVE 1, two distinct strategies based on PCR were used. The first involved synthesis of a pool of HCVE1 cDNA using a mixture of random hexanucleotides as a primer. Then the 3' part of the NS1 gene was amplified from the HCVE1 cDNA pool, by PCR using two specific sets of primers (NS1B/NS1C and NS1D/NS1E) ( Table 1 ). The specificity of the amplification was confirmed by hybridization with a specific oligonucleotide probe (NS 1 B/C) ( Table 1 ). The amplified products were cloned by blunt-end ligation into M13mpl9 and sequenced. The nucleotide sequence of the 5' part of the NS1 gene was not available at the time of the experiment. Therefore, to obtain sequence data for the French isolate, we used a strategy derived from the sequence-independent single (a) Okamoto et al., 1990; Takeuchi et al., 1990a) . The first nucleotide of the sequence corresponds to nucleotide 999 of the HCVpt sequence . (Fig. 2b) . Thus, based on the sequence comparison, our French isolate is closely related to the American HCVpt isolate. Nucleotide sequence comparisons for the five isolates were not available in the 3' part of the NS1 gene. However, it should be noted that the majority of the amino acid changes were located on the 5' part of the E2/NS 1 region when HCVE 1 and HCVpt were compared (Fig. 2b) . In the central region, 10 potential Nglycosylation (N-X-T/S) sites were found conserved in HCVEI and HCVpt (Fig. 2b) .
In this report we have presented the sequence data for two regions of a French HCV isolate, HCVE1. The first one corresponds to the region previously shown to have some sequence homologies with the NS3 gene of flaviviruses (Miller & Purcell, 1990) . The second region corresponds, by analogy with the genetic organization of flaviviruses and pestiviruses, to the flavivirus NS 1 and to the pestivirus Gp53 proteins (Collett et al., 1988) . It is therefore referred to as the E2/NS1 protein. Our data confirm the occurrence of an important degree of genetic variability among HCV isolates (Enomoto et al., 1990; Kato et al., 1989; Kubo et al., 1989; Okamoto et al., 1990; Takeuchi et al., 1990a, b) . At the amino acid level, in agreement with the sequence data, a greater divergence was observed for the E2/NS1 region (12 to 30~) than for the NS3/NS4 region (2 to 79/00) when compared with American and Japanese sequences. Furthermore, four hotspots of amino acid changes could be observed in the 5' part of the E2/NSI domain. It is not clear whether these regions represent areas that mutate in response to host immune selection or whether they represent hypervariable regions prone to genetic drift owing to the lack of stringent structural or functional constraints.
The higher degree of divergence in HCV E2/NSI as well as the N-glycosylation sites might reflect its role as a structural protein. Furthermore, for RNA viruses as a whole, sequence conservation in non-structural regions is generally greater than in structural regions (Strauss et al., 1987) . Finally, the existence of heterogeneous HCV molecules was observed in the serum of our patient. This is consistent with previous observations (Okamoto et al., 1990; Takeuchi et al., 1990a) . The identification of an NSl-related protein in HCV might be important when considering the host immune response to virus infections. Studies on dengue viruses have demonstrated that immunization of mice with the NS1 protein of dengue 2 virus induced resistance to dengue encephalitis (Schlesinger et al., 1987) . Recent data have shown that NSIinduced protection is mediated by complement-dependent cytolytic antibodies (Falgout et al., 1990) . It may be possible to take advantage of these observations in future diagnostic and vaccine strategies.
